MAY 08, 2020 7:31 AM PDT

Cholesterol Drugs May Boost Healthy Gut Bacteria in Obese People

WRITTEN BY: Annie Lennon

While statins have long been known for their efficacy in treating high cholesterol, until recently, there was no evidence on its benefits for the microbiome. Now though, tesearchers have found that obese people who take cholesterol-lowering statin drugs may be more likely to have healthier gut bacteria than those who don’t.

For their study, researchers from the Flanders Institute for Biotechnology in Belgium used data from the European Union study called MetaCardis to explore the link between cardiovascular disease and gut bacteria. The research project is known for having microbiome data from over 2,000 individuals from Europe across 1,400 variables including medication and body-mass index. 

From the 888 samples studied, they found that those with higher levels of Bacteroides 2 (Bact2) enterotype (a certain microbiome configuration) tended to have a higher body-mass index and a higher liklihood of being obese. This is particularly noteworthy as the Bact2 enterotype is associated with inflammation. Previous studies have shown that while 75% of people with inflammatory bowel disease have the enterotype, just 15% of those without it have the condition. 

The researchers also found that the pattern of enterotypes in obese people taking statins significnatly differed from those who do not take the drug. While just 5.9% of those taking statins had the Bact2 entereotype, 17.7% of those not taking the drug had the Pact 2 microbiome configuration. These results were repeated when analyzing data from the Flemish Gut Flora Project. 

The authors of the study caution that although their findings open an interesting avenue for further research, they should not be taken conclusively. When calculating their results, lifestyle and socioeconomic factors for example were not taken into account. More than this, due to the lack of ethnic diversity in their samples, these results may not apply for different ethnic groups. 

 

Sources: Forbes, Nature

 

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
NOV 11, 2020
Health & Medicine
A smart path for novel biologics
NOV 11, 2020
A smart path for novel biologics
Introduction  Cell culture is at the heart of the production process for many biopharmaceuticals, but finding the o ...
NOV 22, 2020
Cannabis Sciences
Synthetic Cannabinoids Linked to Increased Deaths in Older Patients with COPD
NOV 22, 2020
Synthetic Cannabinoids Linked to Increased Deaths in Older Patients with COPD
Researchers from St. Michael’s Hospital in Toronto have found that two synthetic cannabinoids available on prescri ...
DEC 09, 2020
Technology
AI Helps Drug Combination Therapy in Cancer
DEC 09, 2020
AI Helps Drug Combination Therapy in Cancer
Healthcare providers opt to multiple of therapies for cancer patients—often containing combo drugs. Research has s ...
DEC 09, 2020
Drug Discovery & Development
Rapid-Release Capsule for IBS
DEC 09, 2020
Rapid-Release Capsule for IBS
Researchers have developed a rapid-release capsule to treat symptoms of irritable bowel syndrome with constipation (IBS- ...
JAN 05, 2021
Neuroscience
Synthetic Psychedelic Treats Depression Without Hallucinations
JAN 05, 2021
Synthetic Psychedelic Treats Depression Without Hallucinations
Psychedelics are receiving an increasing amount of attention- both in research and in the media- for their potential to ...
JAN 18, 2021
Immunology
Arthritis Drug Approved for Critically Ill COVID Patients
JAN 18, 2021
Arthritis Drug Approved for Critically Ill COVID Patients
Critically ill COVID patients in the U.K. may receive an arthritis drug after a study showed that treatment lowered mort ...
Loading Comments...